<DOC>
	<DOCNO>NCT02474069</DOCNO>
	<brief_summary>This study design support optimal use secukinumab provide data refine guidance dose flexibility patient psoriasis . The purpose study explore effect dosage interval shorteng achieve PASI 90 week 32 patient less almost clear skin week 16 .</brief_summary>
	<brief_title>Secukinumab Dosage Optimisation Partial Responders With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects eligible inclusion study must fulfill follow criterion : 1 . Subjects must able understand communicate investigator must give write , sign date informed consent study relate activity perform willing capable comply study procedure . 2 . Men woman least 18 year age time screen . 3 . Chronic plaque type psoriasis diagnose least 6 month prior baseline 4 . Moderate severe plaque type psoriasis baseline derive European consensus ( Mrowietz et al. , 2011 ) : BSA ( Body Surface Area ) &gt; 10 % PASI &gt; 10 DLQI &gt; 10 . 5 . Candidates biologic therapy fail respond , contraindication intolerant previous conventional systemic therapy . 6 . According local guideline , exclude chest infection initiation biologic immunomodulating therapy , necessary obtain image chest ( Xray , computerize tomography magnetic resonance imaging ) within 12 week prior screen evaluate qualified physician . 1 . Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic guttata psoriasis ) . 2 . Druginduced psoriasis ( i.e. , new onset current exacerbation betablockers , calcium channel inhibitor lithium ) . 3 . Ongoing use prohibit psoriasis nonpsoriasis treatment . Washout period adhere . 4 . Subjects willing limit UV light exposure ( e.g. , sunbathe and/or use tan device ) course study . 5 . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer . 6 . Previous exposure secukinumab ( AIN457 ) biologic drug directly target IL17A IL17A receptor ( e.g . brodalumab , ixekizumab ) . 7 . History hypersensitivity study drug drug similar chemical structure . 8 . Study personnel first degree relative investigator ( ) must include study . 9 . Women pregnant breast feeding ( pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/ml ) ) menstruate capable become pregnant* practice medically approve method contraception ( Pearl Index &lt; 1** ) least 4 week end treatment . A negative pregnancy test ( serum ) woman girls enter menarche require sufficient lead time inclusion *definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/m 6 week post surgical bilateral oophorectomy without hysterectomy **examples particularly reliable method Pearl Index ( PI ) &lt; 1 , accord guideline Deutsche Gesellschaft für Gynakologie und Geburtshilfe : hormonal oral contraception ( Combination estrogen gestagen , PI=0.10.9 ) hormonal vaginal ring ( combination estrogen gestagen , PI=0.65 uncorr . ; 0.4 corr . ) hormonal transdermal patch ( combination estrogen gestagen , PI= 0.72 uncorr . ; 0.9 corr . ) Estrogenfree ovulation inhibitor contain desogestrel ( PI=0.14 ) Implanted hormone contain etonogestrel ( PI=00.08 ) Injectable 3month depot progestin ( PI=0.31.4 ; 0.88 corr . ) Intrauterine progestine device ( synthetic progestin contain IUDs , PI=0.16 ) Oral contraceptive without estrogen ( e.g . `` minipills '' ) , nonsynthetic progesterone IUDs , female condom , cervical shield , periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . 10 . Active ongoing inflammatory disease psoriasis might confound evaluation benefit secukinumab therapy . Patients psoriatic arthritis exclude . 11 . Underlying condition ( include , limited metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious gastrointestinal ) opinion investigator significantly immunocompromises subject and/or place subject unacceptable risk receive immunomodulatory therapy . 12 . Subjects preexist recentonset central peripheral nervous system demyelinate disorder discretion investigator . 13 . Significant medical problem , include limited following : uncontrolled hypertension ( ≥160 systolic and/or 95 diastolic mmHg ) , congestive heart failure [ New York Heart Association status class III IV ] . 14 . Subjects serum creatinine level exceed 2.0 mg/dl ( 176.8μmol/l ) screening . 15 . Screening total white blood cell ( WBC ) count &lt; 2,500/μl , platelet &lt; 100,000/μl neutrophil &lt; 1,500/μl hemoglobin &lt; 8.5 g/dl . 16 . Active systemic infection last two week ( exception : common cold ) prior screen infection reoccurs regular basis . 17 . History ongoing , chronic recurrent infectious disease include recurrent respiratory and/or urinary tract infection evidence tuberculosis infection define positive QuantiFERON TBGold test screening . Subjects positive indeterminate QuantiFERON TBGold test may participate study full tuberculosis work ( accord local practice/guidelines ) complete least 12 week prior first study drug administration establish conclusively subject evidence active tuberculosis . If presence latent tuberculosis establish , treatment must initiate maintain accord local country guideline least 4 week prior screen . 18 . Past medical history record infection human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C prior screen . 19 . History lymphoproliferative disease know malignancy history malignancy organ system within past 5 year ( except skin Bowen 's disease , basal cell carcinoma actinic keratoses treat evidence recurrence past 12 week ; carcinoma situ cervix noninvasive malignant colon polyp remove ) . 20 . Current severe progressive uncontrolled disease judgment clinical investigator render subject unsuitable trial put subject increase risk . 21 . Inability unwillingness undergo repeat venipuncture ( e.g . poor tolerability lack access vein ) . 22 . Any medical psychiatric condition , investigator 's opinion , would preclude participant adhere protocol complete study per protocol . 23 . History evidence ongoing alcohol drug abuse , within last six month screen . 24 . Plans administration live vaccine study period 6 week prior screen . No additional exclusion may apply investigator , order ensure study population representative eligible subject .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>